Numis Securities Ltd reiterated their buy rating on shares of Vectura Group PLC (LON:VEC) in a research note issued to investors on Thursday morning. They currently have a GBX 252 ($3.15) price target on the stock.

Other equities research analysts also recently issued reports about the stock. JPMorgan Chase & Co. reaffirmed an overweight rating and issued a GBX 230 ($2.87) price target on shares of Vectura Group PLC in a research note on Thursday, July 28th. FinnCap reaffirmed a buy rating and issued a GBX 225 ($2.81) price target on shares of Vectura Group PLC in a research note on Tuesday, August 30th. Peel Hunt reaffirmed a buy rating and issued a GBX 200 ($2.50) price target on shares of Vectura Group PLC in a research note on Tuesday, August 30th. Stifel Nicolaus reissued a buy rating and set a GBX 242 ($3.02) target price on shares of Vectura Group PLC in a research report on Friday, July 29th. Finally, Citigroup Inc. reissued a buy rating and set a GBX 215 ($2.69) target price on shares of Vectura Group PLC in a research report on Thursday, July 28th. Eight research analysts have rated the stock with a buy rating, The company presently has an average rating of Buy and an average price target of GBX 222.25 ($2.78).

Analyst Recommendations for Vectura Group PLC (LON:VEC)

Shares of Vectura Group PLC (LON:VEC) traded up 2.33% during mid-day trading on Thursday, hitting GBX 149.10. 2,826,201 shares of the company’s stock traded hands. Vectura Group PLC has a 52 week low of GBX 122.90 and a 52 week high of GBX 200.10. The company’s market cap is GBX 612.23 million. The firm has a 50-day moving average of GBX 137.51 and a 200 day moving average of GBX 148.59.

In other news, insider Trevor Phillips sold 240,841 shares of the stock in a transaction on Tuesday, September 27th. The shares were sold at an average price of GBX 139 ($1.74), for a total value of £334,768.99 ($418,252.11). Also, insider Andrew Derodra purchased 30,000 shares of the firm’s stock in a transaction dated Friday, September 30th. The stock was bought at an average cost of GBX 138 ($1.72) per share, for a total transaction of £41,400 ($51,724.14).

Vectura Group PLC Company Profile

Vectura Group plc is a product development company. The Company focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to pharmaceutical companies.

Receive News & Stock Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related stocks with our FREE daily email newsletter.